[Part I — Financial Information](index=3&type=section&id=Part%20I%20%E2%80%94%20Financial%20Information) [Item 1. Condensed Consolidated Financial Statements](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) Q1 2021 financials show total assets at **$70.8 million**, revenues at **$0.83 million**, and net income of **$1.7 million**, boosted by financing and an unrealized gain [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets reached **$70.8 million** by March 31, 2021, driven by increased cash and investments, with equity growing from stock issuances Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $32,848 | $14,042 | | Short-term investments | $19,088 | $11,625 | | Total current assets | $56,613 | $31,696 | | Total assets | $70,800 | $47,348 | | **Liabilities & Equity** | | | | Total current liabilities | $5,617 | $6,314 | | Common stock warrant liabilities | $12,016 | $2,708 | | Total liabilities | $25,097 | $18,796 | | Total stockholders' equity | $45,703 | $28,552 | | Total liabilities and stockholders' equity | $70,800 | $47,348 | [Condensed Consolidated Statements of Operations and Comprehensive Income](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income) Q1 2021 revenues rose to **$828,000**, but net income fell to **$1.7 million**, impacted by a **$7.5 million** unrealized gain on securities Condensed Consolidated Statements of Operations (in thousands) | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Total revenues | $828 | $309 | | Loss from operations | $(5,326) | $(5,790) | | Other income, net | $7,463 | $72 | | Change in fair value of common stock warrant liabilities | $322 | $8,161 | | Net income | $1,681 | $2,423 | | Net income attributable to common stockholders | $2,058 | $2,525 | | Basic EPS | $0.11 | $0.29 | | Diluted EPS | $0.11 | $0.29 | [Condensed Consolidated Statements of Stockholders' Equity](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Total stockholders' equity rose to **$45.7 million** by March 31, 2021, mainly from **$15.5 million** in PIPE financing and net income - In January 2021, the company issued **7,876,784 shares** in a PIPE financing, raising **$15.5 million** in capital[14](index=14&type=chunk) - Total stockholders' equity increased by **$17.15 million** during the quarter, from **$28.55 million** to **$45.70 million**[14](index=14&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Q1 2021 cash flows show **$4.7 million** used in operations, offset by **$22.0 million** from financing, boosting cash by **$16.8 million** Summary of Cash Flows (in thousands) | Activity | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $(4,707) | $(9,270) | | Net cash (used in) provided by investing activities | $(485) | $13,130 | | Net cash provided by financing activities | $21,997 | $696 | | Net increase in cash, cash equivalents and restricted cash | $16,805 | $4,556 | - The company received **$25.1 million** in gross proceeds from the January 2021 PIPE securities purchase agreement[17](index=17&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes confirm sufficient cash through May 2022, detail a **$25.1 million** private placement, a **$210,000** asset write-down, a **$7.5 million** unrealized gain, and recent acquisitions - The company believes its existing cash, cash equivalents, and investments of **$32.8 million** and **$19.1 million** respectively, will be sufficient to meet cash requirements at least through May 2022[28](index=28&type=chunk) - In January 2021, the company raised **$25.1 million** in a private placement of common stock and warrants[29](index=29&type=chunk)[63](index=63&type=chunk) - A write-down of **$210,000** was recorded for fixed assets related to CBD processing in Hawaii due to legislative delays[37](index=37&type=chunk) - Subsequent to the quarter, the company acquired Agrasys S.A. in Spain and the assets of Lief Holdings (Soul Spring, Saavy Naturals, Provault, Zola brands) for **$4.0 million** in cash and **827,400 shares** of common stock[110](index=110&type=chunk)[111](index=111&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses GoodWheat™ and GoodHemp™ commercialization; Q1 2021 revenues rose **168%** to **$0.8 million**, net income was **$1.7 million** due to a **$7.4 million** unrealized gain, with **$25.1 million** raised ensuring liquidity [Overview](index=24&type=section&id=Overview) Arcadia is a science-based company developing high-value crop improvements in wheat, hemp, and soy, focusing on commercializing innovations through sales and licensing - The company's commercial strategy is to monetize its innovations through sales of seed, grain food ingredients, hemp extracts, trait licensing, and royalty agreements[115](index=115&type=chunk) - Key product lines include GoodWheat™, a non-GM portfolio of wheat products with enhanced nutrition, and GoodHemp™, a brand for hemp seeds, transplants, flower, and extracts[121](index=121&type=chunk)[125](index=125&type=chunk) - The Archipelago Ventures Hawaii joint venture aims to create a vertically integrated supply chain for hemp, from seed to sale, serving Hawaiian, North American, and Asian markets[128](index=128&type=chunk)[129](index=129&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) Q1 2021 revenues rose **168%** to **$828,000**, product sales increased **421%**, R&D fell **48%**, and net income decreased to **$1.7 million** despite a **$7.4 million** unrealized gain Results of Operations Comparison (in thousands) | Metric | Q1 2021 | Q1 2020 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $828 | $309 | $519 | 168% | | Cost of product revenues | $856 | $132 | $724 | 548% | | Research and development | $1,159 | $2,244 | $(1,085) | (48)% | | Selling, general and administrative | $4,069 | $3,723 | $346 | 9% | | Loss from operations | $(5,326) | $(5,790) | $464 | (8)% | | Other income, net | $7,463 | $72 | $7,391 | 10265% | | Net income | $1,681 | $2,423 | $(742) | (31)% | - The increase in product revenues was driven by sales of GoodWheat and additional volume of SONOVA pet food orders[149](index=149&type=chunk) - The decrease in R&D expenses was primarily driven by the company pivoting its focus to commercialization and right-sizing research teams[154](index=154&type=chunk) [Liquidity, Capital Resources, and Going Concern](index=31&type=section&id=Liquidity%20C%2C%20Capital%20Resources%2C%20and%20Going%20Concern) As of March 31, 2021, the company had **$32.8 million** in cash, sufficient to fund operations for at least 12 months, largely due to a **$25.1 million** private placement - As of March 31, 2021, the company had cash and cash equivalents of **$32.8 million**[163](index=163&type=chunk) - The company believes its existing cash and cash equivalents are sufficient to meet anticipated cash requirements for at least the next 12 months[164](index=164&type=chunk) Cash Flow Summary (in thousands) | Activity | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Operating activities | $(4,707) | $(9,270) | | Investing activities | $(485) | $13,130 | | Financing activities | $21,997 | $696 | [Critical Accounting Policies and Estimates](index=32&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) The company identifies critical accounting policies and estimates related to revenue recognition, income taxes, stock-based compensation, fair value of equity instruments, and inventory valuation - Critical accounting policies include revenue recognition, income taxes, stock-based compensation, fair value of certain equity instruments, and net realizable value of inventory[175](index=175&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not required for smaller reporting companies - Not Required[176](index=176&type=chunk) [Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2021, with no material changes to internal controls identified - The President and Chief Executive Officer and the Chief Financial Officer concluded that as of March 31, 2021, the company's disclosure controls and procedures were effective at the reasonable assurance level[178](index=178&type=chunk) - There were no changes in internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[179](index=179&type=chunk) [Part II — Other Information](index=33&type=section&id=Part%20II%20%E2%80%94%20Other%20Information) [Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material litigation or other material legal proceedings - The company is not currently a party to any material litigation or other material legal proceedings[180](index=180&type=chunk) [Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors) This section refers the reader to the detailed risk factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2020 - The report directs readers to the 'Risk Factors' section in the Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of factors that could materially affect the business[181](index=181&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=33&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During the quarter, the company issued unregistered securities in a private placement on January 25, 2021, including common stock and warrants, plus a warrant to an independent contractor - On January 25, 2021, the company entered into a securities purchase agreement for a private placement of **7,876,784 shares** of common stock and warrants for an aggregate of **3,938,392 shares** of common stock[184](index=184&type=chunk) - On January 15, 2021, a warrant to purchase **7,500 shares** of common stock was issued to an independent contractor[183](index=183&type=chunk) [Other Information](index=33&type=section&id=Item%205.%20Other%20Information) On May 16, 2021, the company eliminated the position of chief technology officer, with the employee's final day of employment being May 21, 2021 - The company eliminated the chief technology officer position, with the employee's last day being May 21, 2021[187](index=187&type=chunk) [Exhibits](index=34&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including forms of warrants, purchase agreements, and officer certifications

Table of Contents (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37383 Arcadia Biosciences, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction ...

Financial Data and Key Metrics Changes - The company achieved record revenues of $8 million in 2020, approximately 80% of the initial revenue guidance of $10 million [5][29] - Total revenues increased significantly from $1.2 million in 2019 to $8 million in 2020, primarily driven by GoodWheat licensing revenues [29] - The net loss attributable to common stockholders decreased to $4.7 million in 2020 from $28.8 million in 2019, aided by a non-cash gain of $6.6 million [31] Business Line Data and Key Metrics Changes - The company expanded its product offerings to six categories, including GoodWheat pasta, flour, grain sales, GoodHemp CBD seed sales, CBD oil, and GLA consumer products [6] - GoodWheat license revenues contributed $6.7 million to total revenues, marking a significant increase from previous years [28] - Cost of product revenues rose to $5.2 million in 2020 from $885,000 in 2019 due to inventory write-downs [29] Market Data and Key Metrics Changes - The global wheat flour market was valued at $181 billion in 2019 and is projected to reach $220 billion by 2027, indicating a significant market opportunity for the company [13] - The company noted a contraction in U.S. hemp acreage, particularly for CBD extract, impacting the GoodHemp business [25] Company Strategy and Development Direction - The company is transitioning to a commercial entity focused on food science innovation, leveraging its proprietary non-GM advanced breeding technologies [11] - A comprehensive strategy is being developed to optimize product offerings and expand market reach, particularly in consumer packaged goods [15][16] - The company aims to become the gold standard in wheat, emphasizing the nutritional benefits of GoodWheat [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's agility and potential for growth as market conditions normalize post-pandemic [33] - The company is well-positioned to capitalize on emerging markets, particularly in the hemp sector, once regulatory clarity is achieved [46] Other Important Information - The company successfully integrated Industrial Seed Innovations to enhance its GoodHemp portfolio and accelerate its breeding program [22] - The balance of cash and cash equivalents was $60 million at the end of 2020, bolstered by a private equity placement [32] Q&A Session Summary Question: Update on R&D pipeline from trait discovery process - Management confirmed ongoing advancements in trait discovery for both hemp and wheat, with a shift towards food innovation [36][38] Question: Plans for growing inventory and Good Mills launch - Management indicated plans for inventory growth in preparation for a Good Mills launch in Europe, with optimism about testing in Q2 [41][42] Question: Timetable for hemp revenues and Canadian partner expectations - Management expects the majority of GoodHemp revenues in Q2, with ongoing shipments to Canadian partners pending Health Canada approval [66][67]

GoodWheat Business - The global wheat market represents a significant opportunity, estimated at $16 billion[12] - GoodWheat offers nutritional advantages, including 30% less calories, 6x more fiber, and 2x more protein compared to conventional wheat[13] - Arcadia Biosciences sources Identity Preserved (IDP) grain in the US and manufactures finished goods like flour, pasta, and cake mixes[17] - B2C GoodWheat indicative revenues project $2 million in annual product revenue with 500K units sold, and $4 million with 1,000K units sold, assuming an average MSRP of $4 per pack[25] - B2B GoodWheat indicative revenues project $1 million in annual grain revenue with 100K units sold, and $2 million with 200K units sold, assuming a pricing of approximately $10 per bushel[27] GoodHemp Business - The global hemp market is projected to reach multi-billion dollar by 2025[29] - Umpqua hemp variety produces 2 to 25 pounds of biomass per plant, flowering in late July, with CBD levels near 10%[34] - Archipelago Ventures, a joint venture, aims to create a vertically integrated CBD supply chain from seed to sale[38] - Archipelago Ventures indicative revenues project $25 million in annual CBD retail revenue with 100K units sold, and $63 million with 250K units sold, assuming an MSRP of $25[40] - Archipelago Ventures indicative revenues project $16 million in annual CBD revenue with 40 acre harvests[41] Financial Highlights - As of 9/30/20, Arcadia Biosciences had $489 million in cash, $21 million in debt, and 213 million shares outstanding[54] - Analyst price targets for RKDA range from $450 to $905, implying values between $96 million and $193 million[54]

Financial Data and Key Metrics Changes - Revenues decreased by 20% quarter-over-quarter but increased by 20% year-to-date, driven by initial GoodWheat grain sales and increased GLA product sales [72] - Total operating expenses for Q3 2020 were $7.9 million compared to $6.6 million in Q3 2019, with year-to-date operating expenses totaling $21.2 million versus $16.1 million in the same period of 2019 [73] - Cash on hand and cash equivalents totaled $10.2 million at the end of Q3, with an additional $2 million in restricted cash [76] Business Line Data and Key Metrics Changes - The HB4 soybean business was consolidated with Bioseries, providing Arcadia with $6 million in cash and 1.875 million shares of Bioseries stock, enhancing liquidity and reducing future capital contributions [18][25] - GoodWheat products were launched directly to consumers, with positive feedback on nutritional content and taste, indicating strong market potential [7][9][10] Market Data and Key Metrics Changes - The U.S. CBD market is projected to reach $4.7 billion in 2020, with a 14% growth from 2019, despite challenges due to the pandemic [57] - The market opportunity for GoodWheat is significant, with expectations of a 15% premium over conventional wheat prices, translating to potential annual royalties of approximately $11 million for Arcadia [22][23] Company Strategy and Development Direction - The company aims to drive near-term shareholder value by focusing on the commercialization of its products, particularly through partnerships and direct-to-consumer channels [4][30] - The strategic partnership with Bioseries is expected to enhance geographic reach and operational efficiency in South and Central America [5][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for GoodWheat products, citing consumer trends towards healthier food options during the pandemic [31][48] - The company is focused on reducing overhead costs and reallocating resources to customer acquisition and direct-to-consumer marketing strategies [70][120] Other Important Information - The company experienced a $1.3 million write-off of archipelago hemp inventory due to regulatory issues affecting CBD processing [75] - The acquisition of Industrial Seed Innovations is expected to enhance the GoodHemp product line and improve market positioning [56] Q&A Session Summary Question: What prompted the timing of the deal with Bioceres? - The timing was driven by a transition from development to commercialization, with Bioseries taking the lead in the commercialization phase [83] Question: What factors are important for sustainable top-line revenue growth? - The direct-to-consumer channel for GoodWheat is expected to yield immediate results, with marketing efforts aimed at gaining new customers [85] Question: What are the implications of recent marijuana legalization for Arcadia's business? - Legalization is expected to positively impact the hemp market, facilitating further legalization and extraction processes [87] Question: Can you provide more details on the inventory write-offs? - The write-offs were primarily due to regulatory clarity issues affecting CBD processing, and the company does not expect similar write-offs in the future [89] Question: What is the expected revenue from Sunova GLA capsules in China? - Projected revenues for the China market are estimated at $1.8 million for fiscal year 2021 [100] Question: What is the status of the backlog for GoodHemp seeds? - The backlog remains, but the focus is now on fulfilling orders for the 2021 planting season rather than emphasizing the backlog [114]

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants Matthew Plavan - President & CEO Pamela Haley - CFO Randy Shultz - Chief Technology Officer Conference Call Participants Ben Klieve - National Securities Corporation Steven Ralston - Zachs Robert Smith - Center for Performance Investing Operator Good afternoon, and welcome to Arcadia Biosciences Second Quarter 2020 Earnings Conference Call. Today's presenters will be Matt Plavan, Presiden ...

Financial Data and Key Metrics Changes - Revenue in Q1 2020 was $151,000 higher than in Q1 2019, primarily driven by licensees' milestone achievements [43] - Total operating expenses for Q1 2020 were $6.1 million, an increase of 39% compared to $4.4 million in Q1 2019 [44] - Net income attributable to common stockholders for Q1 2020 was $2.5 million, compared to a net loss of $12.6 million in Q1 2019 [46] - Cash on hand at the end of Q1 2020 totaled $60 million, up from $25.3 million at year-end [48] Business Line Data and Key Metrics Changes - The hemp backlog remained unchanged at $3.7 million due to a pause in commitments during April, but orders are expected to decline as shipments are fulfilled [15] - The HB4 soybean project has secured regulatory approval on more than 80% of global soybean acres, with sales expected to begin in 2021 [16] - GoodHemp seeds are anticipated to generate significant revenue in Q2 2020, transitioning from backlog to sales [26] Market Data and Key Metrics Changes - The COVID-19 pandemic has impacted the business, with some hemp growers delaying purchases, but interest has increased significantly in May [12] - The company is experiencing a market increase in deal flow as growers resume spring plantings [13] - The wheat business is expected to see initial revenue from European shipments in Q2, with more substantial sales in Q3 and Q4 [40] Company Strategy and Development Direction - The company aims to accelerate shareholder value creation through strategic growth opportunities in the hemp value chain [20] - A focus on vertical integration is emphasized, with plans to capture greater value in the supply chain by combining strong genetics with processing capabilities [56] - The company is committed to acting as a responsible corporate neighbor in Hawaii, where it has expanded operations [31] Management's Comments on Operating Environment and Future Outlook - Management believes the worst of the COVID-19 pandemic is behind them and expects to recover delayed sales in the coming months [17] - The company maintains its revenue guidance of over $10 million for 2020, supported by anticipated sales from GoodHemp, CBD, and wheat [17] - Management is optimistic about the hemp supply chain's potential for consolidation and plans to play an active role in these opportunities [22] Other Important Information - The company experienced unusually high cash burn of $9.3 million in Q1 2020, attributed to inventory builds and capital expenditures [18] - A $1.1 million loan was secured under the Paycheck Protection Program, with plans to apply for forgiveness [50][82] Q&A Session Summary Question: Can you discuss the vertical expansion strategy versus horizontal expansion? - Management sees more value in vertical expansion due to risks in the supply chain quality and aims to capture greater value by integrating genetics with processing [56] Question: How is the supply chain quality in Hawaii compared to the Mainland? - The company is well-equipped in Hawaii and plans to focus initial vertical moves on the Mainland [58] Question: Can you provide a breakdown of the inventory build? - The inventory includes a mix of GoodHemp, some in process, and wheat, with visibility provided in the Q [59] Question: What is the outlook for seasonality and revenue breakdown for the next quarters? - The majority of hemp business will flow out in May, June, and July, with wheat sales expected in Q3 and Q4 [61] Question: How can the company capitalize on the trend towards home baking? - Management sees home baking as a strong trend and plans to announce a retail flour partnership in Q2 [66] Question: Can you expand on the hemp hub model and its progress? - The company has established a footprint in several regions, including Hawaii and California, and is building capabilities in other areas [70] Question: What is the status of the HB4 soybean project and Expoagro? - The project has seen strong interest, with ten times more acreage registered than needed, indicating high demand for innovation [77]

Financial Data and Key Metrics Changes - In 2019, the company experienced a 6% reduction in revenues for Q4 compared to the prior year and a 20% reduction for the full year compared to 2018 [31] - The net loss attributable to common stockholders for Q4 2019 was $6.2 million, compared to $646,000 in Q4 2018 [35] - Cash on hand, cash equivalents, and short-term investments totaled $25.3 million at the end of 2019, with net cash used in operating activities for the year at $17.2 million [36] Business Line Data and Key Metrics Changes - The company harvested over 2,300 acres of GoodWheat varieties in 2019, which was ten times more than the previous year [9] - The backlog purchase commitments for good hemp seeds exceeded $3.7 million, representing minimum order commitments from retailers and growers for 2020 [12] - The company reported strong feedback from partners testing GoodWheat varieties, indicating positive results for formulation, taste, and baking performance [14] Market Data and Key Metrics Changes - The legalization of hemp cultivation in late 2018 led to a significant increase in the market for hemp-derived products, with global CBD sales topping $4 billion in 2019 [4] - The company has expanded its HB4 drought-tolerant and herbicide-resistant soybeans to over 80% of the global soybean market, including key regions like the U.S., Brazil, and Argentina [10] Company Strategy and Development Direction - The company aims to become a market leader in high-value hemp seeds and varieties by deploying advanced breeding technologies in partnership with the hemp grower community [11] - The company is focused on building a vertically integrated Hawaiian good hemp supply chain to support commercial scale-up once regulations are finalized [7] - The company plans to launch six new hemp prototype varieties for on-farm evaluation through its hemp innovation partner farmer network [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue projections exceeding $10 million in 2020, supported by strong backlog commitments and ongoing interest in hemp products [38] - The company acknowledged potential impacts from the coronavirus but noted that agriculture is deemed an essential industry, allowing operations to continue [38] Other Important Information - The company has established a research pipeline to deliver new hemp varieties that address market challenges and deliver value across various segments [18] - The company is actively pursuing partnerships with North American soybean seed companies to bring HB4 traits to market [58] Q&A Session All Questions and Answers Question: Can you comment on the revenue guidance and the expected split between hemp and wheat product lines? - Management indicated that hemp seed sales and CBD sales are likely to dominate revenues, with a reasonable split of 60-40 in favor of hemp [41][42] Question: What is the impact of social distancing on wheat consumption? - Management noted a significant increase in milling capacity and production to meet the demand for flour as consumers shift to home cooking [44] Question: What is the potential for GoodWheat's brand lines due to supply chain disruptions? - Management believes both Resistant Starch and Reduced Gluten products are compelling, with the potential for Reduced Gluten to catch up in popularity [47] Question: Can you elaborate on the incremental opportunity for hemp sales this year? - Management expects a significant inflow of commitments in May and June as growers finalize their decisions for spring and summer plantings [54][55] Question: What are the milestones for bringing HB4 into North America? - Management highlighted the importance of partnerships and field trials to evaluate the performance of HB4 traits in North American conditions [56][58]

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q3 2019 Results Conference Call November 6, 2019 4:30 PM ET Company Participants Matt Plavan - President and CEO Sarah Reiter - Chief Commercial Officer Pam Haley - Chief Financial Officer Conference Call Participants Ben Klieve - National Securities Brian Marckx - Zacks Investment Operator Good afternoon, and welcome to the Arcadia Biosciences Third Quarter 2019 Earnings Conference Call. Today's presenters will be Matt Plavan, President and CEO; Sarah Reiter, Chief C ...

Q3 2019 Financial Results and Business Highlights Supplemental Slides November 6, 2019 Forward-looking statements • "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to components of the company's long-term financial success; the company's traits, commercial products, and collaborations; the company's ability to manage the regulatory processes for its trai ...